Cerebral Toxoplasmosis and AIDS (TOXODFA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00803621 |
Recruitment Status :
Completed
First Posted : December 5, 2008
Last Update Posted : July 5, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
With a HIV incidence much higher in the DFA than in European French territory, this disease is a major public health problem in these areas, especially in French Guiana.
Cerebral toxoplasmosis is a priority among the opportunistic infections in AIDS patients from the DFA because of its frequency (French West Indies) and of its lethality (French Guiana).
The diagnosis of cerebral toxoplasmosis may be difficult because based only on presumptive clinical and radiological features. The response to specific antitoxoplasmic therapy confirms a posteriori the diagnosis.
In reference to the data collected by the Biological Resource Centre Toxoplasma, in particular in French Guiana, we think that T. gondii strains reactivating in AIDS patients from DFA are genetically different from those reactivating in AIDS patients from Europe, with an increased capacity for dissemination via peripheral blood in the first ones. This more frequent or more prolonged parasitemia could facilitate the diagnosis of cerebral toxoplasmosis by PCR test from peripheral blood samples in AIDS patients from the French departments of America.
Condition or disease | Intervention/treatment |
---|---|
Cerebral Toxoplasmosis AIDS | Other: Toxoplasma PCR assay |
Study Type : | Observational |
Actual Enrollment : | 46 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Cerebral Toxoplasmosis and AIDS in the French Departments of America (DFA). Diagnostic Contribution of a PCR Assay and Genetic Diversity of Toxoplasma Gondii. |
Study Start Date : | June 2009 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | December 2013 |

- Other: Toxoplasma PCR assay
Toxoplasma PCR assay
- Isolation, genetic typing and storage of T. gondii strains collected among AIDS patients with cerebral toxoplasmosis from the DFA. [ Time Frame: 3 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Adult patient (> 18 years)
- Patient being informed and accepting to participate in the study with signature of informed consent
- HIV positive serology
- Clinical and radiological suspicion of cerebral toxoplasmosis justifying the start of specific antitoxoplasmic therapy
Exclusion Criteria:
- Protected patient
- Patient uncovered by social insurance
- Specific antitoxoplasmic therapy already initiated since 72h or more

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00803621
France | |
Service des Maladies Infectieuses - CHU de Pointe à Pitre | |
Pointe À Pitre, Guadeloupe, France | |
Services Maladies Infectieuses et Tropicales- CHU Fort-de-France | |
Fort-de-France, France | |
Dermatologie et CISIH- CH Andrée Rosemon | |
Guyane-Française, France | |
Maladies Infectieuses et Tropicales - CH Andrée Rosemon | |
Guyane-Française, France | |
Médecine- CH Ouest Guyanais | |
Guyane-Français, France |
Study Director: | Daniel AJZENBERG, PharmD, PhD | CHU Limoges |
Responsible Party: | University Hospital, Limoges |
ClinicalTrials.gov Identifier: | NCT00803621 |
Other Study ID Numbers: |
I07009 |
First Posted: | December 5, 2008 Key Record Dates |
Last Update Posted: | July 5, 2019 |
Last Verified: | December 2013 |
Toxoplasmosis, Cerebral Toxoplasmosis Coccidiosis Protozoan Infections Parasitic Diseases Brain Abscess Abscess Suppuration |
Infection Central Nervous System Protozoal Infections Central Nervous System Parasitic Infections Brain Diseases Central Nervous System Diseases Nervous System Diseases Central Nervous System Infections |